AMD1 and prostate cancer: Indeed, inhibition of ODC1 with difluoromethylornithine (DFMO) is suggested to reduce the risk of colorectal cancer26 and targeting AMD1 with SAM486A reduces prostate cancer growth with negligible systemic toxic effects22.